BDM 0.00% 4.0¢ biodiem limited

read this

  1. 677 Posts.
    BioDiem Ltd
    ABN 20 096 845 993
    Phone: +61 3 9613 4100 Fax: +61 3 9613 4111
    Level 10, South Tower, 459 Collins Street, Melbourne Victoria 3000
    Email: [email protected] Web:
    ASX Announcement
    Date: 29 February 2008
    Target market expands for BioDiem’s Flu vaccine
    Melbourne: 29 February 2008. Australian biopharmaceutical development company
    BioDiem Ltd (ASX:BDM) commented today on new recommendations from the US
    Centers for Disease Control and Prevention’s (CDC) Advisory Committee on
    Immunization Practices (ACIP) to expand the recommended ages for annual influenza
    vaccination to include all children from 6 months to 18 years of age in the United States.
    The previous recommendation was for vaccination of children from six (6) months to 59
    months of age.
    BioDiem’s CEO Dr Andrew O’Brien said, “This recommendation will increase the number
    of school children targeted for seasonal flu shots by 30 million in the world’s biggest
    pharmaceutical market. This is a meaningful change in potential market size for
    BioDiem’s live attenuated influenza vaccine (LAIV) given our vaccines’ advantages in
    this market segment over existing inactivated flu vaccines. Furthermore, this should
    increase the attractiveness of the North American Sales & Marketing rights for LAIV to a
    potential partner.”
    Clinical studies conducted by the Institute of Experimental Medicine in St. Petersburg,
    Russia, indicate that LAIV provides superior protection against influenza when compared
    to an inactivated flu vaccine in children. Furthermore, these studies showed that
    vaccination with LAIV can provide a ‘herd immunity’ whereby the spread of influenza is
    reduced in schools where the majority of the school population has been vaccinated with
    The CDC commented that studies have shown that healthy children bear a significant
    burden from influenza disease and are at increased risk of needing influenza-related
    medical care. In addition, there is evidence showing that reducing influenza
    transmission among children has the potential to reduce influenza among their
    household contacts and within the community.
    Dr. Anne Schuchat, director of CDC’s National Center for Immunization and Respiratory
    Diseases said “this new recommendation will help parents understand that all children
    can benefit from vaccination and further encourages providers to start vaccination of
    children through age 18 next year”.
    About BioDiem’s Live Attenuated Influenza Vaccine
    �� BioDiem has licensed the majority of the LAIV rights to Nobilon, a subsidiary
    company of Schering-Plough for US$8 million in milestone payments and royalties on
    product sales
    �� Nobilon has the responsibility for developing the flu vaccine for registration in Europe.
    The product is currently in non-clinical development
    �� BioDiem retains the Sales and Marketing rights to North America, subject to an
    option Nobilon has to these rights under certain terms, if no other partner is licensed
    by BioDiem 2 years after the commencement of Phase III clinical trials
    �� Japanese Sales and Marketing rights are shared between BioDiem and Nobilon
    About BioDiem Ltd
    BioDiem is an Australian listed company, based in Melbourne, with an international focus
    on finding, adding value to and commercialising world-class research for vaccines,
    infectious diseases and other therapeutic areas. The company takes a cost-efficient
    approach to drug development by project managing a portfolio of new products through
    collaborations with academic centres of excellence, contract research organizations and
    partnerships with international pharmaceutical companies.
    For additional information, please visit
    Further information
    Andrew P. O’Brien, Ph.D.
    CEO & Managing Director
    BioDiem Ltd
    Ph: +61 3 9613 4100
    Mob: +61 438 550 893
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.